Zhengye Biotechnology Holding Limited: revenue
Revenue for Zhengye Biotechnology Holding Limited. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Zhengye Biotechnology Holding Limited financial histories
What this measure means
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
Exact concept: us-gaap:Revenues. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2022-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Coverage by original unit
- CNY: 2022-01-01 to 2025-12-31.
- USD: 2024-01-01 to 2025-12-31.
These are separate reported series. A newer period in one unit does not update another unit’s history or establish a currency conversion.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 116,362,000 | CNY | 2026-04-28 | 20-F · 0001213900-26-048584 |
| 2024-01-01 | 2024-12-31 | 186,356,000 | CNY | 2026-04-28 | 20-F · 0001213900-26-048584 |
| 2023-01-01 | 2023-12-31 | 211,651,000 | CNY | 2026-04-28 | 20-F · 0001213900-26-048584 |
| 2022-01-01 | 2022-12-31 | 260,269,000 | CNY | 2025-07-03 | 20-F · 0001213900-25-061202 |
| 2025-01-01 | 2025-12-31 | 16,639,000 | USD | 2026-04-28 | 20-F · 0001213900-26-048584 |
| 2024-01-01 | 2024-12-31 | 25,531,000 | USD | 2025-07-03 | 20-F · 0001213900-25-061202 |
Related financial histories
- Zhengye Biotechnology Holding Limited: total assets
- Zhengye Biotechnology Holding Limited: total liabilities
- Zhengye Biotechnology Holding Limited: stockholders equity
- Zhengye Biotechnology Holding Limited: net income or loss
- Zhengye Biotechnology Holding Limited: operating cash flow
- Zhengye Biotechnology Holding Limited: capital expenditure payments
- Zhengye Biotechnology Holding Limited: contract revenue excluding tax
- Zhengye Biotechnology Holding Limited: financing cash flow
- Zhengye Biotechnology Holding Limited: investing cash flow
- Zhengye Biotechnology Holding Limited: retained earnings or deficit
- Zhengye Biotechnology Holding Limited: basic weighted-average shares
- Zhengye Biotechnology Holding Limited: diluted weighted-average shares
- Zhengye Biotechnology Holding Limited: basic earnings per share
- Zhengye Biotechnology Holding Limited: diluted earnings per share
- Zhengye Biotechnology Holding Limited: income tax expense or benefit
- Zhengye Biotechnology Holding Limited: net property, plant and equipment
- Zhengye Biotechnology Holding Limited: operating income or loss
- Zhengye Biotechnology Holding Limited: current assets
- Zhengye Biotechnology Holding Limited: current liabilities
- Zhengye Biotechnology Holding Limited: current accounts payable
- Zhengye Biotechnology Holding Limited: net finite-lived intangible assets
- Zhengye Biotechnology Holding Limited: net current accounts receivable
- Zhengye Biotechnology Holding Limited: operating expenses
- Zhengye Biotechnology Holding Limited: net inventory
- Zhengye Biotechnology Holding Limited: gross profit
- Zhengye Biotechnology Holding Limited: cost of revenue
- Zhengye Biotechnology Holding Limited: research and development expense
Inspect the source
- Entity
- Zhengye Biotechnology Holding Limited / CIK 0001975641
- Captured
- 2026-09-21T17:42:27.528Z
- SEC response SHA-256
2cbd390c7cb47f87386fcafc5e54b40724410772d151ffb4716d81e922a20b67
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001975641.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))